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Oral vaccination stimulates neutrophil functionality and exerts
protection in a Mycobacterium avium subsp. paratuberculosis
infection model
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Rakel Arrazuria4, Jeroen De Buck4, Juan Anguita 3,5 and Natalia Elguezabal 1✉
Mycobacterium avium subsp. paratuberculosis (Map) causes paratuberculosis (PTB), a granulomatous enteritis in ruminants that exerts
high economic impact on the dairy industry worldwide. Current vaccines have shown to be cost-effective against Map and in some
cases confer beneficial non-specific effects against other pathogens suggesting the existence of trained immunity. Although Map
infection is mainly transmitted by the fecal-oral route, oral vaccination has not been deeply studied. Therefore, the aim of this study
was to compare the oral route with a set of mycobacterial and non-mycobacterial vaccines with a subcutaneously administered
commercially available vaccine. Training effects on polymorphonuclear neutrophils (PMNs) and homologous and heterologous
in vivo protection against Map were investigated in the rabbit infection model. Oral vaccination with inactivated or live vaccines
was able to activate mucosal immunity as seen by elevation of serum IgA and the expression of IL4 in peripheral blood
mononuclear cells (PBMCs). In addition, peripheral PMN phagocytosis against Map was enhanced by vaccination and extracellular
trap release against Map and non-related pathogens was modified by both, vaccination and Map-challenge, indicating trained
immunity. Finally, PBMCs from vaccinated animals stimulated in vitro with Map antigens showed a rapid innate activation cytokine
profile. In conclusion, our data show that oral vaccination against PTB can stimulate neutrophil activity and both innate and
adaptive immune responses that correlate with protection.
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INTRODUCTION
Johne’s disease or paratuberculosis (PTB) is an infectious granulo-
matous enteritis that primarily affects domestic1 and wild2
ruminants, although it has been detected in other non-ruminant
species including rabbits3,4 and birds, among others5.
Mycobacterium avium subspecies paratuberculosis (Map), the
etiological agent of the disease, is an intracellular bacterium that is
transmitted through the fecal-oral route. It ensures its survival and
dissemination by infecting macrophages and exerting evasion
mechanisms that permit its replication inside this immune cell.
Macrophage infection triggers granuloma formation in the
intestine, in particular in the ileum and ileocecal valve6.
The most common clinical signs of PTB are diarrhea, chronic
weight loss, and decrease in production, which imply a premature
elimination of animals and economic losses7. The control of this
disease is based mainly on the improvement of herd management
and the test and cull strategy, but vaccination has shown to be a
cost-effective method8 against PTB, decreasing the number of
clinical cases, reducing bacterial shedding in feces9,10 and
improving milk production10. A commercial inactivated Map
vaccine has shown heterologous protection against other
mycobacterial infections11 and reduction in overall mortality in
dairy cattle12, effects that could emerge from innate trained
mechanisms or from cross-reactive T-cell mediated adaptive
immunity. This vaccine has also shown priming of monocyte-
derived macrophages as seen by increased Map killing activity
compared to non-vaccinated animals13. All these findings suggest
that trained immunity, such as that observed with the BCG vaccine
in human newborns against Mycobacterium tuberculosis (Mtb),
Candida albicans, and Staphylococcus aureus, can indeed be
behind this effect14.
Despite the demonstrated beneficial effects of current com-
mercial PTB vaccines, they are not allowed in cattle in most
countries due to the interference with bovine tuberculosis (bTB)
diagnostic tests15. Interference can be avoided or reduced by the
introduction of variations in the diagnostic methods15,16, but this
requires modifications in legislation that are difficult to achieve.
Another approach to avoid interference with bTB diagnosis, is to
apply vaccines through alternative routes as shown for an
inactivated M. bovis (Mbv) vaccine in cattle17 and goats18 or a
Map inactivated vaccine in guinea pigs19. In PTB, the oral route is a
good alternative since it is the route of natural infection. However,
mucosal immunity activation, disease protection, and absence of
interference with bTB diagnosis through this delivery method
need to be demonstrated.
Ruminant infection models of PTB are widely used for
vaccination studies20. However, the lengthy incubation of the
disease in ruminants added to the expenses of the experiments
have led to the development of non-ruminant laboratory animal
models. In this sense, rabbits which are naturally susceptible to
infection with Map3,4 and have shown to be useful short term
models to study the effect of diet on infection21 and to evaluate
vaccination22, can be suitable to screen novel vaccines since many
key aspects of PTB can be studied in this model20.
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A better understanding of PTB pathogenicity and immune
protection associated to vaccination is also needed in order to
develop new effective vaccines. Several studies have addressed
the importance of polymorphonuclear neutrophils (PMNs) in the
innate immune protection against Mtb23,24 and very recently,
BCG-induced protection has been shown to be dependent on
PMNs25, showing they can undergo long-term functional repro-
gramming26. Additionally, the induction of specific Th1 and Th17
responses as a consequence of PMNs modulation by vaccination
has demonstrated bacterial load reduction27, uncovering a
“training capacity of PMNs”. The presence of PMNs at disease
sites in the initial phases of mycobacterial infections has been
demonstrated28–30. However, their role in defense against Map
has only been suggested by recent transcriptomic studies
describing the impairment of PMN recruitment and activation
during PTB31–33. PMNs from healthy cattle have shown to exert
extracellular trap (ET) formation and killing effects against Map
in vitro34. The idea that proper PMN activation or training by PTB
vaccines could eventually prevent or mitigate the effects of Map
infection is a hypothesis that should be tested.
In this work we performed a vaccination-challenge Map
experiment seeking evidence of protection against PTB via oral
vaccination and possible trained immunity and cross- protection
exerted by both mycobacterial and non-mycobacterial vaccines
through ex vivo neutrophil functional assays. We have found that
oral vaccination with inactivated or live Map vaccines is able to
activate mucosal immunity as well as peripheral PMN function-
ality. In addition, oral vaccines showed increased neutrophil
responsiveness to heterologous stimulations and an innate
activation cytokine profile with protective effects against PTB in
the rabbit Map infection model.
RESULTS
In order to assess mucosal and systemic immunity activation and
disease protection through oral delivery we tested mycobacterial
inactivated and live attenuated vaccines and a non-mycobacterial
inactivated vaccine in the rabbit Map infection model following
experimental scheme on Fig. 1. Specifically, an inactivated Map
vaccine (MPV), a live attenuated vaccine (LAV), an M. bovis
inactivated vaccine (MBV) and a C. pseudotuberculosis inactivated
vaccine (CPV). In our experimental design, the isolation of PMNs
from this combination of vaccinated animals along with homo-
logous and heterologous stimuli would also permit assessing if
these inactivated vaccines are capable of exerting training effects
indicative of heterologous protection.
Oral vaccination increases phagocytosis of Map by
neutrophils
One of the main mechanisms that contribute to bacterial
clearance by PMNs is phagocytosis so we assessed if oral
vaccination would affect PMN phagocytic capacity. PMNs were
isolated at different time points and exposed to Map-GFP ex vivo.
Oral LAV and CPV and subcutaneous CV vaccination showed
enhanced neutrophil phagocytosis against non-opsonized Map-
GFP 4 weeks after first dose of vaccine administration (PV1)
compared to non-vaccinated animals (NV) (Fig. 2a). This activity
was maintained after Map challenge in some cases. At PV3
(12 weeks later) for CPV and CV vaccinated animals (Fig. 2c) and
even after 16 weeks (PV4), a slight effect was still conserved for CV
(Fig. 2e). Interestingly, CPV, a non-mycobacterial vaccine was able
to activate PMNs for Map phagocytosis indicating that hetero-
logous activation is possible.
Phagocytosis against opsonized Map-GFP with autologous
plasma was increased in PMNs isolated from CV, LAV, and MBV
vaccinated animals 4 weeks after the first dose at PV1 (Fig. 2b).
PMNS from CV and MPV animals showed enhanced phagocytosis
after Map challenge at PV3 (Fig. 2d), which was only maintained
by CV PMNs at PV4 (Fig. 2f).
Map-GFP phagocytosis by PMNs correlated positively with anti-
PPA3-antibody levels under opsonized conditions, as expected, at
all sampling points (PV1: ρ= 0.77, p < 0.0001; PV3: ρ= 0.83 p <
0.0001 and PV4: ρ= 0.76, p < 0.0001). CV was the group with the
highest phagocytic activity and Map-antibody titres. Oral vaccina-
tion was less efficient at maintaining a long-lasting elevated
specific phagocytic activity of circulating PMNs and at boosting a
specific humoral response (IgG and IgM) (Fig. 2g).
Vaccination and Map challenge induce extracellular trap
release by neutrophils
PMNs from healthy animals are also capable of releasing ETs
against pathogens such as S. aureus35, E. coli36, and Map34 or
Mbv34, so we assessed if ex vivo NET formation was affected by
vaccination and challenge against mycobacterial and non-
mycobacterial microorganisms and NETosis levels were repre-
sented on a heat-map (Fig. 3a). PMNs isolated from animals
vaccinated with MPV showed enhanced NET release against Map
and Mbv (heterologous effect) at PV1 compared to NV (Fig. 3c, e).
At this same time point all other tested vaccines showed
decreased NET release compared to NV, suggesting that this
mechanism is not predominant at this time point in those groups.
At PV3 (two months after challenge and 3 months after first dose
Fig. 1 Experimental scheme. Interventions and sampling points used to study trained immunity in ex vivo functional assays and protection
in vivo after infectious challenge with Map.
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vaccination), NET release was increased in PMNs isolated from CV
against Map (Fig. 3d), from CPV animals against Map and Mbv
(again heterologous training effect) (Fig. 3d, f) and from MPV
animals against Cpstb (also heterologous) (Fig. 3h). The combina-
tion of vaccination and challenge is probably what triggers an
enhanced response of PMNs against Map in the CPV group.
Interestingly, PMNs from MBV (Fig. 3e, f) and CPV (Fig. 3g, h)
animals showed an inhibition on ET release when stimulated
ex vivo with the microorganisms that the vaccines were targeted
for (secondary exposure), Mbv and Cpstb, respectively. This
inhibitory effect was observed in both time-points PV1 and PV3
meaning that the challenge with Map did not affect PMN behavior
of MBV and CPV against Mbv and Cpstb, respectively.
ET release against S. aureus (Fig. 3i) and E. coli (Fig. 3h) was
generally increased at PV3 (2 months after Map challenge and
3 months after first dose vaccination) in all challenged groups.
ET release against Map and Mbv positively correlated both in
PV1 and PV3, (PV1: ρ= 0.8, p < 0.001 and PV3: ρ= 0.57, p < 0.0001),
although at PV3 correlation strength dropped, suggesting that
although vaccination could exert innate cross protective effect in
PMNs, in vivo challenge with Map could have reverted this effects
or further changed some group’s PMNs behavior against
mycobacteria.
Vaccination enhances PMN aggregation trapping and
surrounding Map in vitro
NETosis was also observed by microscopy (Fig. 3b). PMN behavior
among experimental groups from PV1 varied after in vitro
incubation for 4 h as seen in micrographs with Map-GFP (Fig. 4)
and Map (Supplementary Fig. 5). PMNs from vaccinated groups
aggregated around the mycobacteria, arranging to form bigger
and more compact clusters compared to the NV group. The
observed aggregates contained Map-GFP bacteria forming clumps
surrounded by PMNs and skeins of chromatin threads. In the NV
group, Map-GFP presence outside of PMN aggregates resulted
Fig. 2 PMN phagocytosis levels. Phagocytosis against a, c, e non-opsonized and b, d, f opsonized Mycobacterium avium subsp.
paratuberculosis (Map)-GFP at a, b PV1 (1 month after first dose vaccination), c, d PV3 (2 months after challenge) and e, f PV4 (3 months after
challenge) of non-vaccinated and non-challenged (NV: NC+CC at BV and PV1, mean of n= 9); non-challenged (NC), non-vaccinated and
challenged (CC), commercial Map inactivated vaccine (CV), killed Map strain oral vaccine (MPV), live attenuated vaccine (LAV), killed
Mycobacterium bovis vaccine (MBV) and killed Corynebacterium pseudotuberculosis vaccine (CPV). g Serum anti-PPA3 IgG levels. All values for
vaccinated groups were means of n= 5 with error bars representing standard deviation and Kruskal–Wallis with Dunn’s post-hoc test was
applied. Blue asterisks represent significant differences compared to the NC group, purple asterisks compared to the CC group and
signification levels are *<0.05, **<0.01, ***<0.001.
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more frequent and the observed clusters of PMNs were smaller
and less compact.
Vaccination elevates lactate levels in plasma indicating
immune activation
There is evidence on the link between aerobic glycolysis and
activated or proliferating cells, due to the increase in their metabolic
demand37. In order to have more evidence on immune activation
by oral vaccination, lactate levels were measured in peripheral
plasma samples from BV, PV1, PV2, and PV3 samplings (Fig. 5a).
The increase in lactate at PV1 compared to BV was higher
compared to the NC group for CV (p = 0.011), MBV (p= 0.019)
and CPV (p= 0.009) (Fig. 5b) indicating a metabolic demand
was taking place after vaccination. MPV also showed a
considerable increase at PV1, though it was not significant
(p= 0.161). On the contrary, LAV, a live Map vaccine did not
show a significant increase of peripheral lactate levels.
Afterward at PV2 and PV3 lactate dropped to baseline levels
in all orally vaccinated groups. Lactate levels at PV3 were
correlated with non-opsonized phagocytosis rates (ρ= 0.67,
p < 0.00001).
Fig. 3 Neutrophil extracellular trap (NET) release levels. NET release against Mycobacterium avium subsp. paratuberculosis (Map),
Mycobacterium bovis (Mbv), Escherichia coli (Ecoli), Staphylococcus aureus (Saur), and Corynebacterium pseudotuberculosis (Cpstb) of animals
vaccinated with commercial Map vaccine (CV), killed Map oral vaccine (MPV), live attenuated vaccine (LAV), killed Mbv vaccine (MBV), and
killed Cpstb vaccine (CPV). a Heatmap representation of raw % NETosis data. b Micrograph image (×40) showing ET release against Map-GFP.
Fold changes referred to non-vaccinated (NV) animals against c Map, e Mbv and g Cpstb (at time-point PV1 (1 month after first dose
vaccination) and against d Map, f Mbv, and h Cpstb referred to non-challenged (NC) animals at time-point PV3 (2 months after challenge). i ET
release increase against Saur at PV3 compared to PV1 for all animal groups. j ET release increase against Ecoli at PV3 compared to PV1 for all
animal groups. All values were means with error bars representing standard deviation from groups of n= 5, except for NC which was n= 4.
ANOVA with Tukey’s post-hoc test was applied. Blue asterisks represent significant differences compared to the NC group, purple asterisks
compared to the CC group and signification levels are *<0.05, **<0.01, ***<0.001.
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Cytokine expression profile and IgA levels suggest that oral
vaccines activated mucosal immunity
In order to characterize the cytokine expression in PBMCs
stimulated by vaccination, gene expression levels of IFN-γ, TNF,
IL-2, IL1-β, IL- 4, IL-12B, IL-10, and IL-23A cytokines were assessed
in isolated PBMCs at 1 month after first vaccination dose (PV1)
(Fig. 6a) and the response of the vaccinated groups were
quantified relative to the NC group, and represented on a heat-
map (Fig. 6b) and further analyzed.
Orally administered LAV, is an attenuated vaccine and the only
live vaccine included in the study. PBMCs from this group
presented high levels of IL-1β (Fig. 6c) and the highest basal
expression of IFN-γ at PV1 (Fig. 6d) indicating a Th1 response. This
is partially expected since it shows the nearest infection-like
profile compared to the rest of the groups. On the other hand, CV
subcutaneous vaccination presented the highest basal expression
of TNF (Fig. 6e) and IL-10 (Fig. 6f). In contrast, MPV was the group
with the lowest IL-10 expression.
As early as 1 month after the first vaccination dose, all oral
vaccines enhanced IL-4 basal expression compared to NC (Fig. 6g).
MPV was the group with the highest IL-4 basal expression,
followed by CPV, MBV, and LAV. In contrast, the subcutaneously
administered CV group presented the lowest basal expression of
IL-4.
This IL-4 elevation suggests that oral vaccines from our study
had activated mucosal immunity. IL-4 elevation is necessary for
mucosal and systemic immunity activation and IgA production38.
Serum IgA levels have been used to predict both vaccine efficacy
and the immune status of individuals or herds against enteric
infectious diseases39, so we decided to measure total IgA in serum
at BV and PV1 hypothesizing that oral vaccination would have
activated the production of this antibody isotype. Indeed, serum
IgA levels increased only in orally vaccinated animals (Fig. 6g, blue
line), showing highest increase for CPV.
MPV vaccine shows the most convenient basal profile of
immune modulation whereas CPV induced highest levels
of IL-1β
Taking into account the expression of the studied cytokines, MPV
is the group showing the best basal pro-inflammatory/Th2
balance at PV1, showing the highest IL-4 expression, a significant
TNF increase, and the lowest IL-10 expression. The group showing
the highest basal levels of IL-1β was CPV, in contrast to MPV,
which showed the lowest levels, while IL-10 expression was
moderate compared to the rest of the groups.
IL-1β basal increase correlated with increased phagocytosis
activity of neutrophils
IL-1β basal levels and phagocytosis at PV1 were positively
correlated (non-opsonized: spearman ρ= 0.54, p= 0.002;
opsonized Map: spearman ρ= 0.57, p= 0.001). This is partially
expected since PBMC derived IL-1β plays a role in neutrophil
recruitment, activation and inhibition of neutrophil
apoptosis40.
Fig. 4 Micrographs of PMNs in contact with Map. a NV, b CV, c MPV, d MBV, e LAV, and f CPV at PV1 after 4 h incubation with Map-GFP (×10).
DAPI (blue), anti-histone (red), and Map-GFP (green).
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Exposure of PMBCs to Map antigens in vaccinated groups
induces an innate immune activation profile
In order to assess the impact of vaccination on the cytokine
expression in PBMCs after ex vivo exposure to Map antigens, gene
expression was relatively quantified from PBMCs isolated at PV1
and stimulated with Map sonicate (SM) for 24 h with respect to the
expression without stimulation (PBS) (Fig. 7a) and represented on
a heat-map (Fig. 7b).
All the vaccinated groups showed an innate immune activation
response (elevated IL-1β, TNF, IL-23A) after exposure to Map
antigens compared to the NC group (Fig. 7d, e, g). IL-10 was also
highly increased in all vaccinated groups indicating regulation of
the inflammatory response (Fig. 7h). Actually, no increase of IFN-γ,
nor IL-4 expression was achieved in any group with respect to
their non-stimulated control. These results can be explained by
the high expression of IL-23, which promotes the differentiation of
naive CD4+ T cells into Th17 cells that produce IL-6, IL-17, IL-17F,
and TNF, but not IL-4 and IFN-γ41.
On the other hand, MPV showed the highest IL-12B levels (Fig.
7c) and CV showed the highest IL-2 values (Fig. 7f).
A discrete pro-inflammatory polarization was observed in
GALT from challenged animals and CV showed the most
lymphoproliferative profile
In order to profile local immune response to Map at the final stage
of the experiment expression of the same cytokines studied in the
peripheral response was analyzed from GALT (Fig. 8a) and
challenged groups’ responses were relatively quantified with
respect to the NC group and represented on a heat-map (Fig. 8b).
In general, all challenged groups showed a more pro-
inflammatory profile in the GALT at the end-point compared to
the NC group, based on the higher local expression of IL-12B in
these groups (Fig. 8c). IL-1β expression was also slightly higher for
all challenged groups compared to the NC except for CV (not oral
vaccine) (Fig. 8d). However, only CC and MPV showed significant
differences.
IL-2 considered the major T lymphocyte growth factor, also
necessary for memory lymphocyte T differentiation42. In this study,
the highest local expression of IL-2, was shown by the CV group
(Fig. 8f). This increase in IL-2 levels could be an indicator of vaccine
efficacy since it plays an important role in the initiation and
maintenance of antigen-specific immune responses43. CV also
showed higher local IL-4 expression compared to CC, indicative of
lymphocyte B proliferation (Fig. 8g).
The expression of IL-12B and IL-2 resulted positively correlated
(ρ= 0.42, p < 0.0001) and the strength of the correlation between
IL-12B and IL-2 increased in GALT of those animals with
demonstrated Map colonization of tissues (ρ= 0.73, p= 0.003).
MPV and CPV vaccinated animals presented lowest Map tissue
colonization
In order to partially assess protective effects of the oral vaccines in
this subclinical model of infection, Map isolation from tissues was
performed on two different culture media augmenting the
isolation probability and data are shown on Tables 1 and 2.
Map was not isolated in any samples from the NC group as
expected. Only one GALT tissue (SAC) from the CV tested positive
in HEYM culture. In the CC group three out of five animals were
Fig. 5 Lactate levels in plasma. a Lactate level changes in plasma throughout sampling points. b Lactate level increase of vaccinated groups
with respect to NC during the period between PV1 (1 month after first dose vaccination) and BV (before vaccination). Blue asterisks represent
significant differences between vaccinated or challenged groups with NC and purple asterisks represent significant differences between
vaccinated groups and CC. All values were means with error bars representing standard deviation from groups of n= 5, except for NC which
was n= 4. Kruskal–Wallis with Dunn’s post-hoc test was applied and signification levels are *p < 0.05, **p < 0.01.
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positive for Map in HEYM or TiKa. The best results amongst orally
vaccinated groups are those from MPV and CPV with only one and
two positive tissues, respectively.
LAV positive cultures in HEYM or TiKa were re-cultured in 7H9
OADC MJ with hygromycin. No colonies were observed confirming
that colonies from tissue cultures from this group belonged to the
challenge strain.
Principal component analysis of immune parameters shows a
homogeneous and well-differentiated immune shaping by
MPV and CPV oral vaccines
In order to visualise the global impact of vaccination immunolo-
gical parameters were considered for a principal component
analysis (PCA). Although Map isolation from tissues was not
considered for the PCA, the groups that the analysis located in the
center (LAV, CC, and MBV) were coincident with the groups
showing highest Map tissue positivity, while the groups located in
the periphery were the groups with most Map negative tissues
(NC, CV, CPV, and MPV). Moreover, CV, CPV, and MPV, were also
represented separately from each other, reflecting the differences
in their immune modulation outcome probably due to the
differences in vaccine composition and administration route
(Fig. 9a–c).
The CV vaccinated group displays a large and distant ellipse,
consistent with the strong, but heterogeneous effects that are
seen in the group (Fig. 9a). This vaccine triggers different
activation levels in the animals, showing, for instance, high
antibody titres in some animals and low values in others. In
contrast, oral MPV and CPV, display more compact ellipses,
indicating moderate and homogeneous effects in the groups
(Fig. 9b).
CC and NC are closely displayed (Fig. 9b, c), probably because
Map tissue culture has not been considered, Map replicates slowly
Fig. 6 Cytokine relative quantification by RT-qPCR of PBMCs isolated from animals at PV1 (1 month after first dose vaccination) relative
to the NC. a Schematic representation of sample origin. b Heatmap representation of cytokine expression of vaccinated groups; in red
upregulated and in green downregulated gene expression. Bar charts showing log2 fold change between vaccinated groups and NV. c IL-1β, d
IFN-γ, e TNF, f IL-10, g IL-4 and blue line represents serum total IgA level fold PV1-BV. h Table summarizing the significant differences between
groups in cytokine expression and the Absolute Fold Change Factor. All values were means with error bars representing standard deviation
from groups of n= 5, except for NV which was n= 5. ANOVA with pooled SD with Benjamini & Hochberg correction was applied and
signification levels are *p < 0.05, **p < 0.01, ***<0.001.
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inside macrophages intending to evade the immune system, thus,
provoking minimum reaction is beneficial for its’ survival. Also,
both groups undergo less stimulations in contrast to the
vaccinated groups.
The impact of the parameters on the principal components is
shown on Fig. 9d–g. In general, this analysis shows that oral MPV
and CPV vaccines, led to homogeneous responses, and a singular
response, far from NC and CC, comparable to the subcutaneously
administered CV commercial vaccine, indicating that these can be
promising candidates for oral vaccination.
DISCUSSION
PTB is a worldwide disease mainly affecting domestic ruminants’
health and production, but also posing a potential zoonotic
threat44. Available commercial vaccines show good results in field
studies8. Also, beneficial non-specific effects in terms of overall
mortality reduction in vaccinated herds have been reported12,
although the underlying immunological mechanisms behind
these non-specific effects have been object of research only
recently13. Besides, these vaccines present some negative aspects
to overcome, such as, some interference with bTB diagnostic
tests15. This problem may be solved by changing the vaccination
route from subcutaneous to oral19, though mucosal immunity
activation through this route must be tested. In our study we have
shown that mucosal activation is possible through oral vaccination
(even with inactivated vaccines), and that vaccination against PTB
with experimental vaccines (Map inactivated and C. pseudotuber-
culosis inactivated) and with a Map commercial vaccine is able to
enhance neutrophil functionality (showing trained immunity
effects) as seen by increased phagocytosis and ET release,
important mechanisms for bacterial clearance.
PMNs are able to efficiently phagocytose pathogens by
opsonization with complement factors or antibodies45. Also,
bovine PMNs have been reported to express several membrane
TLRs46, which have shown to increase phagocytosis47. In our study,
we observe an increased non-immune phagocytosis (in the
absence of opsonins) by PMNs of orally vaccinated rabbits, which
is most prominent one month after vaccination but temporary,
lasting up to 3 months after vaccination for vaccine CPV. This non-
opsonized phagocytosis could be linked to an increased expres-
sion of pattern recognition receptors (PRPs) on the surface of
PMNs from vaccinated animals as seen in PMNs from BCG
vaccinated humans that show anti-bacterial functions for at least
3 months after vaccination and changes in PMN phenotype,
toward the expression of activation markers26. Also, lactate levels
were correlated with non-opsonized phagocytosis in PV3, being
the CV group the main contributor to this correlation. It may be
that CV is inducing high levels of granulopoiesis in bone marrow
that require elevated aerobic glycolysis resulting in lactate
increase, phenomenon that has also been reported for BCG48.
Phagocytosis of antibody-opsonized bacteria was higher than
non-opsonized phagocytosis in most cases and highest in the CV
control group correlating with higher levels of specific anti-Map-
antibody levels in plasma. In PTB, the possible protective effect of
antibodies has been questioned and the shift to humoral response
has been related to clinical stages of the disease and severe
lesions49. However, recent studies have demonstrated that the
Fig. 7 Cytokine relative quantification by RT-qPCR of PBMCs isolated from animals at PV1, after ex vivo stimulation with Map sonicate
(SM), of the studied vaccination groups relative to their correspondent non-stimulated control (PBS). a Schematic representation of
sample origin. b Heatmap representation of the average expression of cytokines; in red upregulated and in green downregulated expression.
Bar charts showing log2 fold change between groups. c IL-12B, d IL-1β, e TNF, f IL-2, g IL-23A, h IL-10. i Table summarizing significant
differences between groups in cytokine expression and the Absolute Fold Change Factor. For IL-1β, TNF, IL-23A, and IL-10 only the higher and
the lower Absolute Fold Change and p-values are detailed. All values were means with error bars representing standard deviation from groups
of n= 5, except for NC which was n= 4. ANOVA with pooled SD with Benjamini & Hochberg correction was applied and signification levels are
*p < 0.05, **p < 0.01, ***< 0.001.
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humoral response is necessary for vaccine protection50. Our
findings suggest that during the first months after vaccination
with CV PMN functionality is increased, we hypothesize that
activation may occur through upregulation of surface PRPs but
once antibody levels increase, immune phagocytosis would be
predominant and, in this case, antibodies would be helpful if
phagocytes encounter extracellular Map.
ET formation by PMNs is an important effector mechanism for
pathogen clearance51. ET release results presented in this study
suggest a certain degree of immunity training exerted by oral
vaccination that correlates with protection. Firstly, groups with the
lowest Map tissue positivity (CV, CPV, and MPV) show, at some
point (one month or three months after vaccination) higher ET
release than the non-infected control group when challenged
in vitro with Map. Secondly, PMNs from CPV and CV groups are
the ones showing the highest ET release, which also happened to
be the groups showing the best PMN phagocytosis response,
these are the groups with highest PMN activation or training
levels.
Interestingly, in some cases, this training or functional activation
is heightened by Map oral challenge. One month after vaccination
(PV1), PMNs of all orally vaccinated groups, showed lower ET level
release against E. coli compared to CV and control groups,
whereas after Map challenge (PV3) ET release levels increased for
all challenged groups. This phenomenon was also observed
against S. aureus. Also, worth mentioning is the finding that
vaccines CPV and MBV did not show antigen-specific response to
self antigen. This could be due to some type of self tolerance as
that seen in macrophages when low doses of LPS fail to activate
histone marks in promoters of genes involved in phagocytosis
pathways resulting in a lower inflammatory response of macro-
phages to subsequent stimulation52 or the activation of different
defense mechanisms due to vaccination.
What takes PMNs to release ETs or to phagocytose pathogens
remains a mystery53 and many microorganisms have not been
tested yet for their ability to stimulate ET release. Actually, this is
the first time NETosis has been reported against Cpstb in vitro.
Interestingly, high ET release is not always associated with the
control of the disease54. Indeed evidence is accumulating that
excessive production of NETs is related to the exacerbation of
inflammation and the development of autoimmunity, cancer
metastasis, and inappropriate thrombosis55. We believe that a
good PTB vaccine should potentiate phagocytosis, rather than
NETosis considering that Map is an intracellular bacterium.
Oral vaccines enhanced early IL-4 expression in circulating
PBMCs, which is known to be a relevant cytokine for mucosal
immunity shaping38. Added to this, total serum IgA increased after
vaccination in the oral vaccinated groups pointing in the same
Fig. 8 Cytokine relative quantification by RT-qPCR in GALT at the end point of the experiment of all challenged groups relative to the
NC. a Schematic representation of sample origin. b Heatmap representation of the average expression of cytokines; in red upregulated and in
green downregulated gene expression. Bar charts showing log2 fold change between groups. c IL-12B, d IL-1β, e TNF, f IL-2, g IL-23A, h IL-10, i
Table summarizing significant differences between groups in cytokine expression and the Absolute Fold Change Factor. All values were means
with error bars representing standard deviation from groups of n= 5, except for NC which was n= 4. ANOVA with Tukey’s post-host test was
applied and signification levels are *p < 0.05, **p < 0.01, ***<0.001.
Table 1. Bacteriological analysis results of the control groups.
Group NC CV CC
ID 31 33 34 35 1 2 3 4 5 26 27 28 29 30
HEYM – – – – – – – – SAC – SAC – VA VA
TiKa – – – – – – – – – – MLN – – –
Negative results with “–“ symbol; positive results show with abreviations
indicating the sample tissue: Sacculus rotundus (SAC), vermiform appendix
(VA), mesenteric limph node (MLN).
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direction being highest for CPV, which also shows high PMN
activation and low Map tissue positivity. On the contrary, the
subcutaneous administration of CV did not elevate either IL-4 or
serum IgA. CV caused an increase in IL-10, and also high TNF and
low IL-4 expression in circulating PBMCs we hypothesize due to
granuloma formation at the inoculation site as seen for Mycopar®,
another commercially available whole-cell bacterin containing
inactivated Map56. MPV vaccine showed the most convenient
basal profile of immune modulation regarding protection at
PV1 showing the highest IL-4 expression, significant TNF and IFN-γ
increases and lowest IL-10 expression. IL-10 has been described to
have a role in immune tolerance57 and the blockage of IL-10
during immunization has demonstrated better pathogen clear-
ance results in some studies58. The results of our study could
support the idea that maintaining IL-10 levels low during
immunization could be a good approach to avoid mucosal
tolerance of Map.
Upon in vitro re-stimulation of PBMCs with Map sonicate
(ex vivo secondary exposure), in general, an innate immune
activation driving inflammatory response was characterized by
increased IL-1β, TNF, and IL-23A expression, accompanied by an
increase of the regulatory IL-10. This IL-10 elevation has also been
reported for this vaccine in a study that involved in vitro infection
of caprine monocyte-derived macrophages with Map13 and for a
recombinant protein cocktail vaccine calves59. Regarding PTB,
there are discrepancies, since both the presence59 and absence60
of IL-10 after in vitro estimulation with Map have been associated
to protection. MPV was the only group showing high IL-12B (p40)
and IL-23A (p19) levels. IL-12 gene expression and secretion have
been associated to protection59. High levels of IL-23 should be
desirable since it has been linked to bacterial burden reduction
and maintenance of a Th17 CD4 population in Mtb vaccination61.
Primed IL-1β response by gut monocytes and DCs, is considered
to enhance gut protection, due to its role in inflammatory cell
recruitment62 and PBMC derived IL-1β participates in neutrophil
recruitment and activation and inhibition of neutrophil apopto-
sis40. In our study, all vaccinated animals showed an increased IL-
1β expression a month after vaccination (just before challenge)
upon re-stimulation with Map sonicate. Furthermore, early IL-1β
basal increase correlated with increased phagocytic activity of
neutrophils. In this sense, the vaccine triggering highest basal
levels of IL-1β was CPV.
The GALT cytokine expression profile at the end point of the
experiment showed a discrete pro-inflammatory response in most
of the challenged animals, including all vaccinated groups and CC.
The subclinical nature of the infection model is probably
contributing to this fact. CV showed the highest lymphoprolifera-
tive expression in comparison to the oral vaccines probably due to
the administration route and the persistence of the granuloma
generated at the injection site, which has shown to correlate in
size to anti-PPA3 antibody levels in the previous works19.
There has been controversy on whether inactivated vaccines
maintain their innate training effects, mainly because evidence
from human clinical data has claimed that the beneficial non-
specific effects would be limited to live vaccines63, as seen by
comparison of BCG and gamma-irradiated BCG64. On the other
hand, there is proof that a vaccine composed of cell wall
components from Mycobacterium phlei in oil-emulsion was able to
decrease overall mortality in feedlot cattle65, and also to improve
survival after enterotoxigenic E. coli challenge in neonatal cattle66.
In any case, we believe that this training effect in inactivated
vaccines should be revised since we have demonstrated cross
protective effects of heterologous inactivated vaccines against
PTB in the present study. On the other hand, live-attenuated
vaccines against PTB have also been orally tested in goats
compared to CV67. In that study, some of the experimental
vaccines showed low protective capacity in terms of reduction of
bacterial burden in tissues, as has happened in our study. The
authors claim that oral vaccination might not be appropriate for
delivery of live attenuated vaccines against PTB in the goat model.
Incorporating an adjuvant to these vaccines and fine dose and
time tuning can also be considered.
Data presented here have been obtained in the rabbit infection
model and should be confirmed in ruminants. The results
regarding trained immunity mechanisms obtained in this model
are most probably similar in ruminants and will include training of
PMNs and monocytes as seen in this study and in that conducted
by Arteche Villasol et al.13, respectively. As for protection, we
assume that the rabbit oral challenge model is suitable for
subcutaneous and oral vaccine screening because it is susceptible
to Map3,4 and it is a good model of intestinal inflammatory
conditions68 but these findings must be demonstrated in
ruminants.
In conclusion, we show that oral vaccination with inactivated
bacteria is able to activate mucosal immunity and that PMNs can
be trained through oral and subcutaneous PTB vaccination as seen
by the increased antimicrobial functions in circulating PMNs upon
stimulation with Map and other non-related pathogens. Attending
to the properties exerted by the presented vaccine prototypes,
CPV has shown interesting characteristics enhancing unspecific,
but protective, PMN activation levels. This immunostimulatory
capacity of the CPV vaccine is not surprising since different
Corynebacterium species have shown to be potent immunostimu-
lants69,70. For this reason, it could be worth studying its effect as a
formulation ingredient to be used in combination with the Quil-A
adjuvant and Map bacilli, or as a complement in MPV formulation.
Further future studies should involve assessing if these enhanced
microbial effects are acquired by the entire PMN population or
only by some specific subsets considering that PMNs can be
heterogenous in phenotype and function. Also studying the




All animal procedures were carried out following European, National, and
Regional regulations on animals used in experimentation and other
scientific purposes. The protocols were evaluated and approved by the
Ethics Committee at NEIKER (NEIKER-OEBA-2018-0001) and authorized by
the Regional Council (BFA-38012).
Table 2. Bacteriological results of oral vaccination groups.
Group MPV LAV MBV CPV
ID 11 12 13 14 15 21 22 23 24 25 16 17 18 19 20 6 7 8 9 10
HEYM – – – – – SAC SAC, VA – – – – VA SAC SAC SAC – SAC VA – –
TiKa – – MLN – – SAC – – SAC – – MLN – – MLN – – – – –
Negative results with “–“ symbol; positive results show with abreviations indicating the sample tissue: Sacculus rotundus (SAC), vermiform appendix(VA),
mesenteric limph node (MLN).
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Vaccine and bacteria inoculum preparation
All bacteria used for ex vivo and in vivo challenge assays were grown to
the exponential phase at 37 °C under aerobic conditions.
Vaccines. The MPV vaccine (inactivated Map strain 316F vaccine) was
prepared as described previously in Arrazuria et al.19. The CPV vaccine
(inactivated Corynebacterium pseudotuberculosis field strain vaccine) was
grown in brain heart infusion (BHI) until mid-exponential phase and was
inactivated following the same inactivation protocol as that described for
MPV19. The MBV vaccine (inactivated Mbv strain 1403 vaccine) was
prepared as described in Garrido et al.71. The LAV vaccine (live attenuated
vaccine) was created by allelic exchange mutagenesis as previously
described72 and was grown on Middlebrook 7H9 broth supplemented with
10% OADC, 0.4% glycerol and 2 g/L mycobactin J (7H9 OADC MJ) with
hygromycin (75 µg/ml) and shaking at 140 rpm until exponential phase
(OD600= 0.6–0.8).
Oral challenge. Bovine Map cattle field strain 764 used for challenge was
grown on 7H9 OADC MJ for three weeks and adjusted to 1,5×108 CFU/ml
based on data from growth curves and plating assuming that 0.7 OD is 1 ×
108 bacteria/ml for Map.
Ex vivo assays. Map-K10-GFP (Map-GFP) and M. bovis (Mbv) strain 2008/
2575 were grown for 3 weeks on 7H9 OADC MJ kanamycin (25 µg/ml) and
7H9 OADC, respectively. Escherichia coli (Ecoli), S. aureus (Saur), and C.
pseudotuberculosis (Cpstb) field strains were grown on BHI broth for 24 h in
the case of E. coli and S. aureus and 48 h for C. pseudotuberculosis. Inocula
were adjusted after measuring the optical density at 600 nm and based on
data from growth curves and plating assuming that 0.7 OD is 1 × 108
bacteria/ml for Map, Mbv and Cpstb, 0.4 OD is 2 × 108 bacteria/ml for Saur
and 0.7 OD is 5.6 × 108 bacteria/ml for Ecoli.
Experimental design
New Zealand White female rabbits of 7 weeks of age were purchased from
authorized experimental animal dealers (Granja Cunícola San Bernardo,
Tulebras, Spain) and left on a 15 day acclimatization period. A schematic
representation of the experimental design is shown in Fig. 1. Thirty five
rabbits were housed in cages being divided into seven groups of five
animals each: non-vaccinated and non-challenged group (NC), non-
vaccinated challenged group (CC), subcutaneously vaccinated group with
the commercially available vaccine Silirum® (CV) and four orally vaccinated
groups: live attenuated vaccine (LAV)72, inactivated Map strain 316F
vaccine (MPV)19, inactivated Mbv strain 1403 vaccine (MBV) and
inactivated C. pseudotuberculosis field strain vaccine (CPV). Before
challenge, at initial time points, NC and CC, were considered as one
group and named NV (non-vaccinated). The inactivated commercial
vaccine was administered subcutaneously as a single dose (12.5 mg of
antigen in 1ml) on day 1. All orally administrated inactivated vaccines
Fig. 9 Principal component analysis maps. a–c 3D representation of the spatial disposition that individuals adopt defined by the set of
immune variables assessed in the experiment. d Percentage of explained variances by the top 10 dimensions of the analysis. e Contribution of
variables to Dimension 1; phagocytosis, anti-PPA3 IgG, and lactate levels explain 22.9% of the variation. f Contribution of variables to
Dimension 2; cytokine expression of stimulated and non-stimulated PBMCs explain 13.6% of the variation. g Contribution of variables to
Dimension 3. Cytokine expression levels of sacculus rotundus and lactate (PV1 and PV2) had no impact on the three main principal
components of the analysis. All parameters were from groups of n= 5, except for NC which was n= 4.
I. Ladero-Auñon et al.
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were formulated with Quil-A® adjuvant (InvivoGen) at 50 μg/dose. Oral
vaccines (LAV, MPV, MBV, and CPV) were administered in two doses
(12.5 mg of antigen per dose to match CV antigen quantity as calculated
by wet weight following guidelines for PTB vaccination trials73 in 2ml for
LAV, MPV, and CPV (ranging 3.21–4.06 ×107/dose) and 107 CFU for MBV on
days 1 and 15. On days 32, 33, and 34 all groups except for NC were
challenged orally with one dose of 3 × 108 CFU of Map strain 764 in 2ml of
PBS. Blood sampling for Map PPA-3 ELISA was performed monthly
throughout the study. Neutrophils were isolated from blood for ET release
assays on weeks 4 (PV1) and 12 (PV3) and for phagocytosis assays on
weeks 4 (PV1), 12 (PV3), and 16 (PV4). Also, blood was extracted in heparin
for autologous plasma used in phagocytosis assays on weeks 4 (PV1), 12
(PV3) and 16 (PV4). At the end point, 24 weeks after the start of the
experiment, all animals were euthanized by intracardiac administration of
pentobarbital (Vetoquinol) after deep sedation with xylazine (Calier) and
ketamine (Merial). Tissue samples from the sacculus rotundus (SAC),
vermiform appendix (VA), mesenteric lymph nodes (MLN), tongue, tonsils
and cecal content from SAC were then collected and stored at −20 °C for
Map isolation, since this was considered the experimental endpoint
parameter.
Lactate quantification assay
Lactate levels in plasma samples were quantified using the Lactate-Glo™
Assay (Promega) following the manufacturer’s instructions, using 50 μl of
samples (1:100) and ten two-fold serial dilutions of a lactate standard run
in duplicate in 96-well plates. Luminescence was recorded using a plate-
reading luminometer (Promega). Lactate quantity was obtained extra-
polating sample luminescence values from the standard curve.
PBMC isolation
Seventeen ml of blood were collected from the auricular artery in Acid
Citrate Dextrose vacutainer tubes. Red blood cells (RBCs) were eliminated
by blood dilution 1:2 with 2.4% Dextran/0.9% NaCl. After mixing by
inversion, tubes were left undisturbed for 30min until two different phases
were visible. The upper clearer layer, rich in leukocytes, was transferred to a
50ml tube to pellet the cells by centrifugation at 300 × g for 10 min. After
the supernatant was removed, 10 ml of rabbit leukocyte buffer (NaCl
138mM, KCl 27mM, Na2HPO4 8.1 mM, KH2PO4 1.5 mM, glucose 5.5 mM)
was added to the pellet and the cell suspension was layered on top of
10ml Histopaque® 1119 (Sigma-Aldrich) and centrifuged at 700 × g for
35min at RT, with no brake. The PBMC layer localized between the saline
and the Histopaque® 1119 solution was aspirated and transferred to a new
tube for serial washing in saline. PBMCs were counted on a BIORAD TC20
counter and frozen in RPMI supplemented with FBS (40%) and DMSO
(10%) at −80 °C until use.
PMN isolation
PMNs were isolated from the same 17ml of blood sample passed through
Histopaque® 1119 used for PBMC isolation following a modified protocol
from Siemsen et al.74. After the PBMC layer was aspirated and Histopaque®
1119 was eliminated, PMNs localized in the pellet together with remaining
RBCs were aspirated to a new tube and went through hypotonic lysis with
3ml of distilled water for 30 s. One ml of KCl 0.6 M was then added and the
samples were centrifuged at 300 × g for 10 min. PMNs were suspended in
rabbit leukocyte buffer and counted on a Bio-Rad TC20™ counter. This
isolation protocol yielded PMNs with 94.4 ± 5.9% purity and 98.68 ± 1.1%
viability (Supplementary Fig. 1).
Neutrophil phagocytosis
Phagocytosis was performed in suspension following a previously reported
method with modifications75. Briefly, freshly isolated PMNs suspensions
were prepared in RPMI without phenol red supplemented with 2% FCS at
107 cells/ml. Opsonization of bacteria was performed by incubation in
rotation al 37 °C of 400 μl suspensions of a 1:1 dilution of heat-inactivated
(52 °C, 15 min) autologous plasma in RPMI with L-glutamine and without
phenol red (Gibco). Autologous opsonized and non-opsonized Map-GFP
was added to vials with PMNs at multiplicity of infection (MOI) of 10 and
gently mixed and incubated on a wheel shaker at 37 °C at 16 rpm for
20min.
Live-Dead cells were determined by Hoechst 33258 (H3569, Invitrogen)
staining at 0.025mg/ml for 15min at 4 °C. Cell suspensions were analyzed
using a CytoFLEX Flow Cytometer (Beckman Coulter). Gating strategy is
detailed in Supplementary Fig. 2. Data from the experiments were
depicted as percentages of GFP positive PMNs of at least 10,000 events.
Flow cytometry data were analyzed with CytExpert v2.3 software (Beckman
Coulter). Phagocytosis percentages were expressed as the number of Map-
GFP positive cells divided by the total number of live and single PMNs.
Neutrophil extracellular trap (NET) release quantification
The protocol followed for NET release is a modification of Köckritz-
Blickwede et al.76. Briefly, freshly isolated PMNs were seeded into 96-well
plates at a density of 2 × 105 cells/well. Stimulation was performed with
PMA (Sigma-Aldrich) at 25 nM and S. aureus, E. coli, Cpstb, Mbv, and Map at
MOI 5. Plates were incubated for 4 h at 37 °C 5% CO2. Non-stimulated
PMNs were used as a negative control. The NETs generated by PMNs were
digested with 500mU/ml of s7 nuclease (Roche) for 10min at 37 °C 5%
CO2. Nuclease activity was stopped with 5mM EDTA and culture
supernatants were collected and stored at 4 °C ON. Total DNA was
extracted from non-stimulated PMNs with DNazol supplemented with 1%
polyacryl carrier (Molecular Research Center) following the manufacturer’s
instructions. Extracted DNA was solubilized in TE buffer. Both NETs and
genomic DNA was quantified using the Quant-iTTM PicoGreen® assay
(Thermofisher) according to the manufacturer´s instructions. The plates
were read in a fluorescence microplate reader (Synergy HTX, Biotek) with
filter settings at 488 nm excitation and 520 nm emission. Data from
controls with no cells and non-stimulated cells were subtracted. The
percentage of released NET-DNA was calculated by dividing the amount of
isolated NET-DNA by the DNA genomic content and NETosis levels were
expressed as percentages.
Neutrophil extracellular trap (NET) visualization
Visualization was performed on NETs developed on 16 well chamber slides
(Thermo Scientific) in identical conditions as those described for NET
quantification in the 96-well plates. After the 4 h incubation period, PMN
preparations were fixed with formaldehyde 4% for 15min. Two washes
with PBS were performed and chambers were kept in PBS at 4 °C until
staining was performed. Before staining, cells were permeabilized for
15min with PBS 0.1% TRITON 100, blocked with PBS 1% Goat serum, 0.05%
Tween 20, and 3% BSA. The immunofluorescence staining was performed
with the mouse anti-pan-histone (Merk MAB3422) (1:200) ON at 4 °C. After
3 washing steps with PBS, cells were incubated with anti-mouse Alexa
Fluor 594 (Invitrogen) (1:500) for 30min at RT. After 3 washing steps, cover
slips were mounted on the slides with a drop of mounting medium
containing DAPI. Micrographs were taken on a fluorescence microscope
(Leica-DMi8).
Map culture sonication
Bovine Map cattle field strain 764 strain was sonicated and used for in vitro
stimulation. Briefly, Map was grown in 7H9 OADC MJ broth for three weeks
at 37 °C in aerobic conditions, to an optical density of 0.4 OD at 600 nm.
The culture was centrifuged at 10,000 × g for 20 min and the pellet was
washed twice with cold PBS. The pellet was suspended in PBS and
sonicated three cycles of 5 min at 18W on ice in a Vibra Cell
75186 sonicator. Protein concentration was determined on a spectro-
photometer NanoDrop® and was adjusted to 100 µg/ml.
PBMC stimulation
PBMCs were thawed, washed twice, and incubated in complete medium
(RPMI 1640 with 10% FBS) at 37 °C and 5% CO2. The cells were then
washed, counted, suspended in complete medium, and seeded at 1 × 106
cells/well on 24 well plates and incubated 1 h at 37 °C and 5% CO2 prior to
stimulation. Stimulation was performed with Concanavalin A (Sigma-
Aldrich) (ConA) (2.5 µg/ml), Map sonicate (SM) (10 µg/ml) or left untreated
(PBS). Cultures were incubated for 24 h at 37 °C °C and 5% CO2 and
centrifuged at 300 × g for 8 min for RNA extraction.
RNA isolation and conversion to cDNA of PBMCs and gut
associated lymphoid tissue
RNA isolation from basal and stimulated PBMCs and gut associated
lymphoid tissue (GALT; sacculus rotundus) was performed using the
RNeasy® minikit (Qiagen). Briefly, RLT buffer supplemented with
2-mercaptoethanol was added to 5 × 106 pelleted cells (350 µl) or to
20mg of tissue (600 µl). Disruption and homogenization were performed
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on Tissuelyser II (Qiagen) for cells (one cycle of 30 Hz for 9 min) and tissues
(two cycles of 20-30 Hz for 2 min with a stainless steel bead 7mm per
tube). All samples were stored at −80 °C until use. From this point, the RNA
isolation procedure followed the manufacturer’s instructions. The RNA was
treated with DNAse I (Invitrogen). DNAse treated RNA yield was quantified
using a NanoDrop® spectrophotometer. All the samples were adjusted to
50 ng/ml RNA concentration and were reverse transcribed to cDNA.
cDNA synthesis and RT minus controls of RNA from GALT and PBMCs
were performed on a final volume of reaction 10 µl and 20 ng/µl of RNA
concentration. The reaction contained 4 µl of sample, 0.5 µl of Random
Primers, 0.5 µl Oligo Dt, 0.75 µl of DEPC-water (1.25 µl for RT-controls), 2 µl
of Buffer 5×, 1 µl of MgCl2, 0.5 µl of nucleotide mix, 0.25 µl of RNAsin, and
0.5 µl of GoScript TM reverse transcriptase (0 µl for RT- controls) using the
GoTaq® 2-Step RT-qPCR System (Promega). The RT thermocycler program
followed the manufacturer´s recommendation.
Primers for transcripts of IFN-γ, TNF, IL-2, IL1-β, IL-4, IL-12B, IL-10, and IL-
23A cytokines and IPO8, PGK1, RPLP0, UBE2D1, YWHAZ reference genes
were designed using the IDT online PrimerQuest Tool following MIQE
guidelines77. Primer sequences are detailed on Supplementary Table 1.
Cytokine expression level quantification
Fluidigm (Specific target amplification (STA) and qPCR using the BioMarkTM
HD system) for cytokine expression level determination was performed at
SGIker UPV-EHU. The commercially available Multiplex PCR kit (Qiagen)
was used for the STA of the samples in a final reaction volume of 5 µl,
containing 1.25 µl of the cDNA and 100 nM of primer concentration. The
thermocycler program performed for STA consisted on a stage 1: 95 °C for
15min and a stage 2:12 cycles at 95 °C for 15 s followed for 4 min at 60 °C,
at the end, a final step at 4 °C ∞. Then, STA samples were treated with
Exonuclease I (Thermo Scientific) adding 2 µl of a master mix (1.4 µl DEPC
water, 0.2 µl Exonuclease I Reaction Buffer, 0.2 µl Exonuclease I (20 units/
µl)), to each 5 µl of STA sample and the following program was applied:
37 °C for 30min (Digestion), 80 °C for 15min (Inactivation Exo I) and 4 °C∞
(chill). Then STAs were diluted 1:20 in TE (10mM Tris, 0.1 mM EDTA).
The expression analysis of the pre-amplified Exonuclease I-treated cDNA
was carried out in the qPCR BioMark HD (Fluidigm) nanofluidic system in
combination with 192.24 Dynamic Arrays IFC (IFC) (192 samples, 24 assays).
SsoFastTM EvaGreen® Supermix with Low ROX (Bio-Rad Laboratories). Final
testing conditions for each pair of primers are detailed on Supplementary
Table 1. The 9 target genes were migrated in duplicates. PCR (GE 192 × 24
Fast PCR + Melt v2) protocol was performed: Stage 1 (Hot start): 95 °C for
5 s, stage 2 (Ramp rate 5.5 °C/s): 30 cycles at 96 °C for 5 s and 60 °C for 20 s
and stage 3 (Melting Curve): 60 °C for 3 s and from 60 °C to 95 °C (ramp rate
slow 1 °C/3 s).
Cts (Cycle threshold) and Cqs (Quantification Cycle) results were
analyzed using the Fluidigm Real-Time PCR Analysis Software version
4.1.3. Thresholds were manually adjusted for each primer pair. Apart from
duplicates of STA samples, a no template control (NTC), 8 RT minus, and
five serial 1/5 dilutions from a concentrated sample for the efficiency
analysis were included in the run. The MultiD GenEx vs 6.1 software was
used for calculating: qPCR efficiency, efficiency correction of Cts, replicate
analysis and mean calculation, reference gene stabilization analysis,
normalization of Cqs using the best reference genes and relative
expression calculation using the comparative 2−ΔΔCT method with the
efficiency correction. More information on the analysis for the selection of
the best reference gene combinations for each sample type is detailed in
Supplementary Figs. 2–4.
Map PPA-3 ELISA
Homemade indirect ELISA was performed using Map protoplasmatic
antigen 3 (PPA-3) (Allied Monitor) as previously described78. Briefly, plasma
samples were adsorbed with Mycobacterium phlei in saline solution (5 g/l)
at equal concentrations to reduce cross-reactivity. Microtiter plates were
coated with 0.04mg/mL of PPA-3 diluted in 0.5% sodium carbonate buffer
(pH 9.6). Plasma samples were diluted 1:200 in 0.05% Tween 80 in PBS
(PBS-T) and were assayed (100 µL/well) and protein G peroxidase (P8170,
Sigma-Aldrich) at 0.025 μg/ml) was used. Absorbance was measured at 405
and 450 nm using an automated ELISA plate reader (Multiskan EX®). The
reading obtained at 450 nm was subtracted from the reading of 405 nm to
reduce optical imperfections in the plate. The results are expressed as a
relative absorbance index calculated by dividing the mean absorbance of
the sample by the mean absorbance of the negative control sample.
Map isolation from tissues
For culture on Herrold’s Egg Yolk Medium (HEYM), 0.5 g of collected tissues
were processed. Mesenteric lymph node was sliced in tiny pieces and
weighed, whereas vermiform appendix and sacculus rotundus were
scraped for collection of mucosa and weighed and samples were
processed as described previously22. Briefly, hexadecylpyridinium chloride
(Sigma-Aldrich) 0.76% decontaminated suspensions were centrifuged at
2885 × g during 10min. The supernatant was discarded and the pellet was
washed once with sterile water. After a new centrifugation step in the
same conditions the pellet was suspended in 2 ml of water and four drops/
tube were seeded. All seeded tubes were incubated at 37 °C and checked
for MAP growth at 8, 12, 16, and 20 weeks.
For culture on 7H11 OADC PANTA TiKa MOPT79, 100mg of collected
tissues were sliced and macerated on a Stomacher®. Afterward, these were
treated with TLB buffer supplemented with collagenase and trypsin,
thoroughly mixed and incubated with shaking ON at 37 °C. The digested
tissue was centrifuged at 14,000 × g for 10 min. The pellet was then re-
suspended in 10ml of TiKa-Kic (TiKa Diagnostics) and incubated for 24 h at
37 °C with gentle shaking. Samples were centrifuged at 10,000 × g for
15min at RT. The pellet was re-suspended in 0.2 ml of sterile PBS and
spotted onto 7H11 OADC PANTA TiKa-supplement A MOPT agar plates.
Plates were incubated at 37 °C and checked for MAP growth at 4, 8, and
12 weeks.
Colonies isolated on both medium were confirmed by a real time
multiplex PCR detecting IS900 and ISMap02 Map sequences80. In order to
rule out LAV growth in tissues instead of the Map challenging strain 764,
tissues from animals belonging to the LAV vaccinated group were also
seeded on 7H9 OADC MJ with hygromycin (75 µg/ml).
Statistical analyses
The data were assessed for normal distribution with the normality tests
Shapiro–Wilk and Lilliefors (Kolmogorov–Smirnov). Homogeneity of
variances was assessed with Bartlett’s test. For the statistical analysis of
comparison between means of variables with a normal distribution,
Student’s t test or ANOVA was used with post-hoc multiple comparison as
follows: ET release, Tukey HSD; peripheral and sonicate treated RT-qPCR,
pooled SD and BH correction, GALT RT-qPCR, Tukey HSD. For variables with
a non-normal distribution, the Mann–Whitney U or Kruskal–Wallis tests
were used with post-hoc multiple comparison as follows: phagocytosis,
Dunn’s test with BH correction; Lactate, Dunn’ test. Pearson (ρx,y)
coefficient was calculated for correlation between variables.
At PV1, sampling is performed before challenge and therefore NV
control is used as a sum of CC and NC, as at this time of the experiment
both groups are non-vaccinated groups.
The efficiency of the amplification of each pair of primers was calculated
from the slope of the line resulting from the linear regression of the serial
dilutions GenEx software corrects the raw Cqs using the efficiencies.
Reference Gene stability analysis and normalization were also performed
using the GenEx software, which uses NormFinder81 and GeNorm82
algorithms. For normalization, the geometric mean of the best combina-
tion of reference gene Cqs of each sample was subtracted to each sample
Cq for every target gene.
2−ΔΔCT quantification method was performed with respect to the NC
group for basal PBMC and sacculus rotundus expression, and with respect
to non-stimulated PBMCs for stimulated PBMCs. The logarithmic transfor-
mation of the relative quantities Log2 RQ has been used as input for Fold
change, calculation statistical analysis and plot and graph representation.
The absolute Fold Changes were calculated using the expression: log2Fold
change.
For the PCA analysis the following parameters were taken into account:
phagocytosis of opsonized and non-opsonized Map-GFP at PV1, PV3, and
PV4; NETosis percentages against Map, Cpstb, Mbv, Ecoli, and Saur at PV1
and PV3; anti-PPA3-IgG/IgM ELISA results at PV1, PV2, PV3, PV4, and PV5;
total serum IgA levels at PV1; plasma lactate levels at PV1, PV2, and PV3;
expression of all assayed cytokines in PBMCs at PV1; expression of all
assayed cytokines in PBMCs stimulated with Map sonicate for 24 h at PV1
and expression of all assayed cytokines in GALT at EP of the experiment.
All the statistical tests were performed using R studio desktop (version
1.2.5033). (RStudio Team (2019). RStudio: Integrated Development for R.
RStudio, Inc., Boston, MA URL http://www.rstudio.com/). A p-value <0.05
was considered statistically significant.
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Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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